scout

Matthew P. Goetz, MD

Articles by Matthew P. Goetz, MD

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

ByHope S. Rugo, MD,Nadia Harbeck, MD, PhD,Priya Rastogi, MD,Joyce O’Shaughnessy, MD,Frances Boyle,Javier Cortés, MD,Matthew P. Goetz, MD,Erika P. Hamilton, MD,Chiun-Sheng Huang,Elżbieta Senkus,Alexey Tryakin,Patrick Neven, MD, PhD,Jens Huober, MD,Ran Wei,Valérie André,Maria Munoz,Belen San Antonio,Ashwin Shahir,Miguel Martin, MD, PhD,Stephen Johnston
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

ByMatthew P. Goetz, MD,Masakazu Toi,Jens Huober, MD,Joohyuk Sohn,Oliver Trédan,In Hae Park,Mario Campone,Shin-Cheh Chen,Luis Manuel Manso,Shani Paluch-Shimon,Orit C. Freedman,Joyce A. O’Shaughnessy,Xavier Pivot,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Antonio Llombart,Valérie André,Abhijoy Saha,Gertjan van Hal,Ashwin Shahir,Hiroji Iwata,Stephen R.D. Johnston

Tamoxifen, Endoxifen, and CYP2D6: The Rules for Evaluating a Predictive Factor

ByMatthew P. Goetz, MD

In the post–Human Genome Project era, “personalized medicine” has become a buzzword. Health-care professionals increasingly have access to gene sequence data, with the promise that this information will improve the health of the individual. In the area of breast oncology, the study of genetic markers associated with clinical outcome has been a relative success story.

Latest Updated Articles